Bacteremia caused by the novel species Mycobacterium canariasense.
Campos-Herrero
M I
MI
Servicio de Microbiología, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35020, Las Palmas de Gran Canaria, Canary Islands, Spain. mcamnavl@gobiernodecanarias.org
García
D
D
Figuerola
A
A
Suárez
P
P
Campo
C
C
García
M J
MJ
D000328:Adult; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000382:microbiology*; D002440:Cefoxitin / Q000627:therapeutic use; D020878:Device Removal; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D009161:Mycobacterium / Q000145:classification / Q000302:isolation & purification*; D009164:Mycobacterium Infections / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D002440:Cefoxitin; D000583:Amikacin